Assessing the Feasibility of Screening and Treating Anxiety and Depression in the Bone Marrow Transplant Population
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04025190|
Recruitment Status : Completed
First Posted : July 18, 2019
Last Update Posted : July 18, 2019
|Condition or disease|
Show Detailed Description
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||20 participants|
|Target Follow-Up Duration:||6 Months|
|Official Title:||Assessing the Feasibility of Screening and Treating Anxiety and Depression in the Bone Marrow Transplant Population|
|Actual Study Start Date :||February 22, 2018|
|Actual Primary Completion Date :||May 25, 2018|
|Actual Study Completion Date :||August 28, 2018|
All patients seen in the UNC Bone Marrow Transplant clinic who are candidates for allogeneic transplantation attending their pre-admission visit were approached to offer study participation. Study participation included completion of surveys over a time period up to 60 days after their transplant.
- Systematic screening for depression and anxiety using the Hospital Anxiety and Depression Scale [ Time Frame: Day 0 ]Assess the feasibility of systematic screening for depression and anxiety using the Hospital Anxiety and Depression Scale in adult patients who are allogeneic HSCT candidates.
- Satisfaction among patients and providers participating in the collaborative care model [ Time Frame: Day 0 ]Assess the feasibility of implementing a collaborative care model through assessment of intervention satisfaction scores among participating patients and their health care providers.
- Severity of post-transplant outcomes as defined by an investigator-designed post-transplant outcome index in relation to Hospital Anxiety and Depression Scale scores [ Time Frame: Day 0 ]Explore an association between an investigator-designed post-transplant outcome index (listed below) in patients undergoing allogeneic transplantation and Hospital Anxiety and Depression Scale scores. Aggregated outcomes abstracted from the medical record included: (a) number of days spent in hospital during transplant admission, (b) number of missed clinic appointments, (c) development of acute GVHD, (d) development of chronic GVHD, (e) admission to ICU within first 100 days of transplant, (f) date of neutrophil engraftment, (g) frequency of viral reactivation requiring antiviral treatment, and (h) death in the first 100 days.
- Change in anxiety or depression as measured by the Hospital Anxiety and Depression Scale. [ Time Frame: Day 0 ]Explore whether patient's symptoms of depression and/or anxiety change over time within a collaborative care model.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04025190
|United States, North Carolina|
|Eliza Park, MD|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||Eliza M Park, MD||UNC Chapel Hill|